Autologous bone marrow derived mesenchymal stem cell therapy for osteonecrosis of femoral head: A systematic overview of overlapping meta-analyses

Madhan, Jeyaraman and Sathish, Muthu and Rashmi, Jain and Manish, Khanna (2020) Autologous bone marrow derived mesenchymal stem cell therapy for osteonecrosis of femoral head: A systematic overview of overlapping meta-analyses. Journal of Clinical Orthopaedics and Trauma. pp. 134-142.

Full text not available from this repository.

Abstract

abstract
Study design: Systematic Review. Objectives: We performed this systematic overview on the overlapping meta-analyses that analyzed autologous bone marrow-derived mesenchymal stem cell(BM-MSC) therapy along with core decompression(CD) for the management of osteonecrosis of the femoral head(ONFH) and identify which study provides the current best evidence on the topic and generate recommendations for the same.
Materials and methods: We conducted independent and duplicate electronic database searches in PubMed, Web of Science, Embase, Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effects till September 2020 for meta-analyses that analyzed the efficacy of BM-MSC therapy along with CD for ONFH. Methodological quality assessment was made using Oxford Levels of Evidence, AMSTAR scoring, and AMSTAR 2 grades. We then utilized the Jadad decision algorithm to
identify the study with the highest quality to represent the current best evidence to generate the recommendation. Results: 6 meta-analyses fulfilling the eligibility criteria were included. The AMSTAR scores of the included studies varied from 4 to 9 (mean:7) and all the included studies had critically low reliability in their summary of results due to their methodological flaws according to AMSTAR 2 grades. The current best evidence showed that utilization of BM-MSC therapy along with CD for ONFH resulted in significant improvement in Harris hip scores at 12 and 24 months along with a significant reduction in the necrotic
area of the femoral head and the rate of conversion to total hip arthroplasty(THA) without a significant rise in adverse events due to the procedure. Conclusion: Based on this systematic overview, we give a Level II recommendation that BM-MSC therapy
is more efficacious along with CD in the management of ONFH compared to CD alone. BM-MSC therapy provides better pain relief with significant functional improvement and delaying the collapse of the femoral head thereby preventing further treatment such as THA.

Item Type: Article
Subjects: Mesenchymal Stromal Cells
Meta-analysis
Hip Surgery
Divisions: Regenerative Medicine
Depositing User: Mr Repository Admin
Date Deposited: 04 Oct 2023 07:00
Last Modified: 30 Jun 2024 06:10
URI: https://ir.orthopaedicresearchgroup.com/id/eprint/162

Actions (login required)

View Item
View Item